Orléans, France

Thibault Saurat

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Université D'orleans. Active years: 2019.


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thibault Saurat: Innovator in Pyrimidine Compounds

Introduction

Thibault Saurat is a notable inventor based in Orléans, France. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds. His work has implications for therapeutic applications, showcasing the intersection of innovation and healthcare.

Latest Patents

Thibault Saurat holds a patent for "Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof." This invention relates to compounds of the general formula (I), which are designed for various therapeutic uses. His innovative approach in this area highlights the potential for new treatments in medicine.

Career Highlights

Throughout his career, Thibault has been associated with prestigious institutions such as the Centre National De La Recherche Scientifique and the Université d'Orléans. His work at these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Thibault has collaborated with notable colleagues, including Marie-Aude Hiebel and Sylvain Routier. These partnerships have enriched his research and fostered a collaborative environment for innovation.

Conclusion

Thibault Saurat's contributions to the field of chemistry, particularly through his patent on pyrimidine compounds, demonstrate his commitment to innovation and therapeutic advancements. His work continues to inspire future research in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…